CORRESP Filing
Vor Biopharma Inc.
Date: Feb. 2, 2026 · CIK: 0001817229 · Accession: 0001193125-26-033517
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293052
Letter
RE: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-293052) Request for Acceleration of Effective Date Requested Date: February 4, 2026 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-293052) (the “ Registration Statement ”) to become effective on February 4, 2026, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, David Brinton at (202) 776-2989.
Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 February 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford
Very truly yours,
Vor Biopharma Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 February 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford RE: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-293052) Request for Acceleration of Effective Date Requested Date: February 4, 2026 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-293052) (the “ Registration Statement ”) to become effective on February 4, 2026, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, David Brinton at (202) 776-2989. Very truly yours, Vor Biopharma Inc. By: /s/ Sandy Mahatme Name: Sandy Mahatme Title: Chief Financial Officer